264 Remote Genetic Education, Risk Assessment, and Testing (Generate) for Pancreatic Cancer: A Randomized Clinical Trial

Rodriguez, Nicolette J.; Furniss, C. Sloane; Yurgelun, Matthew B.; Ukaegbu, Chinedu; Constantinou, Pamela E.; Fortes, Ileana; Caruso, Alyson; Schwartz, Alison; Underhill-Blazey, Meghan; Kenner, Barbara; Nelson, Scott H.; Okumura, Sydney; Zhou, Alicia Y.; Coffin, Tara B.; Uno, Hajime; Horiguchi, Miki; Ocean, Allyson J.; McAllister, Florencia; Lowy, Andrew M.; Klein, Alison P.; Madlensky, Lisa; Petersen, Gloria M.; Garber, Judy E.; Lippman, Scott M.; Goggins, Michael; Maitra, Anirban; Syngal, Sapna

doi:10.1016/s0016-5085(23)01065-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, studies have reported a notably higher detection of variants among patients with metastatic disease compared to those with earlier stage disease. This variability underscores the multifaceted nature of genetic predisposition in pancreatic cancer and highlights the need for comprehensive evaluation and classification of variants in clinical practice [12,13].…”

Section: Discussionmentioning

confidence: 99%

Uncovering Pathogenic Variants in Cancer Susceptibility Genes through Genetic Testing for Pancreatic Cancer Patients

Potska,

Katseli,

Agiannitopoulos

et al. 2024

Preprint

View full text Add to dashboard Cite

Pancreatic cancer stands out as one of the most lethal forms of malignancies, representing 2% of all cancer cases and contributing to 5% of cancer-related fatalities. Therefore, early detection of pancreatic cancer is crucial for enhancing treatment outcomes. Various hereditary cancer syndromes have been linked to an elevated risk of developing pancreatic cancer, suggesting potential benefits from surveillance strategies for individuals at risk. Presently, precision medicine employs PARP inhibitor therapy for pancreatic cancer patients carrying germline variants in Homologous Recombination Repair (HRR) genes. Our objective was to ascertain the occurrence of germline pathogenic/likely pathogenic variants in genes predisposing to cancer among pancreatic cancer patients. Methodologically, we analyzed 184 pancreatic cancer patients referred to our laboratory for genetic examination. Utilizing a Next-Generation Sequencing (NGS) approach, we scrutinized 52 genes implicated in hereditary cancer predisposition. Our findings revealed that 21% of the patients analyzed harbored germline pathogenic/likely pathogenic variants. Within this subset, 48% exhibited positive results in pancreatic cancer susceptibility genes, namely ATM (17%), BRCA1 (12%), BRCA2 (7%), CDKN2A (7%), and PALB2. Significantly, 64.3% of the pathogenic variants were associated with genes involved in the HRR pathway (ATM, BRCA1, BRCA2, BRIP1, CHEK2, FANCL, MRE11, PALB2, RAD50, RAD51B and RAD51C). In conclusion, our study underscores the significance of multigene genetic testing for pancreatic cancer patients, with 21% of individuals yielding findings linked to pancreatic or other cancer predisposition. Moreover, patients carried pathogenic/likely pathogenic variants in HRR genes, potentially benefiting from targeted therapies such as PARP inhibitors or platinum-based treatments.

show abstract

Section: Discussionmentioning

confidence: 99%